InvestSMART

The article you are trying to access does not exist, however, here are some articles you may be interested in.

Clinuvel Pharmaceuticals Limited (ASX:CUV)

ALERT: Price-sensitive ASX Announcement for CUV
Current share price for CUV : $7.080 -3.61 (-33.77%)+
Announcement
Release
27 Aug 2026 12:21PM
Price at Release
$10.690
Full Release
download
Summary
CLINUVEL PHARMACEUTICALS LTD (ASX: CUV) reported in its Appendix 4E and Annual Report for the Australian financial year ended 30 June 2026 that revenue from ordinary activities decreased 1% to A$94.0 million, profit before tax fell 8% to A$47.7 million, and net profit attributable to members declined 6% to A$33.9 million, while the company remained debt free, increased cash reserves 12% to A$252.1 million, lifted net tangible assets per share to A$5.35, and declared a fully franked final dividend of A$0.05 per share with record date 4 September 2026 and payment date 18 September 2026; the report highlights a tenth consecutive annual profit and a strategy centred on North American expansion, continued growth of SCENESSE® for erythropoietic protoporphyria including Health Canada approval in July 2026, advancement of the Phase III vitiligo program with CUV105 completed and topline results planned for late 2026, progress on NEURACTHEL® and controlled-release peptide platform VLRX-L, expanded U.S. specialty centre and investor access initiatives including Nasdaq ADS trading from 20 July 2026, and consideration of a full Nasdaq listing and ASX delisting as part of a broader diversification plan to build multiple melanocortin-based revenue streams.
Key Points
  • Reporting period covers 1 July 2025 to 30 June 2026.
  • Revenue from ordinary activities decreased 1% to A$94,024,398.
  • Profit from ordinary activities before tax attributable to members decreased 8% to A$47,659,765.
  • Net profit for the period attributable to members decreased 6% to A$33,916,819.
  • A fully franked final dividend of A$0.05 per ordinary share was declared.
  • Dividend record date is 4 September 2026 and payment date is 18 September 2026.
  • Net tangible assets per security increased to A$5.35 from A$4.77.
  • Cash reserves increased 12% to A$252.1 million.
  • The balance sheet remained debt free.
  • FY2026 marked CLINUVEL’s tenth consecutive annual profit and ninth consecutive annual dividend.
  • SCENESSE® remained the company’s only approved therapy for EPP and doses administered rose to more than 21,000 implants.
  • North American specialty centres increased to 134, including 129 in the U.S. and 5 in Canada.
  • Health Canada granted a Notice of Compliance in July 2026 to market SCENESSE® for adult EPP patients in Canada.
  • The first Phase III vitiligo study CUV105 completed treatment and follow-up, with topline results planned for December 2026.
  • The second Phase III vitiligo study CUV107 was being designed with commencement targeted for late 2026.
  • NEURACTHEL® Instant manufacturing was validated and the first European regulatory submission is expected in the second half of 2026.
  • The VLRX-L controlled-release liquid peptide platform advanced into preclinical development.
  • PhotoCosmetics launch was deferred to 2027 to prioritise the vitiligo program.
  • CLINUVEL’s ADS uplift to Nasdaq Level II trading as CUVL commenced on 20 July 2026.
  • The company announced consideration of a full Nasdaq listing and delisting from the ASX.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.